Industry News-Guangzhou Evidence-Based Pharmaceutical Technology Co., Ltd

2026-08-14

External Expert Reappointment List of the Center for Drug Evaluation (2026 First Batch) (Draft for Comments)

In order to ensure the scientific and impartial nature of drug evaluation and fully leverage the role of external experts in the drug review process, and in accordance with the Measures for the Management of External Experts of the Center for Drug Evaluation, the Center for Drug Evaluation has organized and carried out the reappointment of external experts. External experts submitted reappointment applications to the Center based on factors such as personal willingness, age, and conflicts of interest. After review by the Center in accordance with established procedures, the External Expert Reappointment List of the Center for Drug Evaluation (2026 First Batch) (Draft for Comments) has been formulated.

Learn more

2026-08-10

Four Departments Jointly Issue: The New Edition of the Good Clinical Practice for Drug Trials Is Here!

Today (June 8), in order to optimize the quality management of drug clinical trials, further cultivate a standardized and efficient clinical R&D ecosystem, and support biopharmaceutical R&D innovation, the National Medical Products Administration, together with the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control Administration, issued the revised Good Clinical Practice for Drug Trials (Announcement No. 50 of 2026).

Learn more

2026-07-09

Notice on the Issuance of the National Essential Medicines List (2026 Edition)

In order to implement the decisions and arrangements of the Party Central Committee and the State Council, and to consolidate and improve the national essential medicines system, and in accordance with the Basic Healthcare and Health Promotion Law, the Drug Administration Law, and other legal provisions, the National Health Commission has organized the updating and revision of the National Essential Medicines List (2018 Edition), and has formulated the National Essential Medicines List (2026 Edition).

Learn more

2026-06-24

2025 Drug Clinical Trial Volume Reaches New High, Offering New Treatment Options for Patients

The National Medical Products Administration (NMPA) released the 2025 Annual Report on the Progress of New Drug Registration Clinical Trials in China, reporting 5,215 clinical trial registrations for the year, surpassing 5,000 for the first time. Category I innovative drugs accounted for 72.4% of all new drug trials, with Phase I innovative drug trials ranking first globally. The report provides a comprehensive review of clinical trial data across multiple therapeutic areas, including anti-tumor drugs, weight-loss medications, cell and gene therapies, pediatric medicines, and rare disease drugs, while also offering insights into the current state of China’s original innovation capabilities in new drug R&D and the development of international multi-regional clinical trials.

Learn more

2026-02-28

The 2026 National Conference on Traditional Chinese Medicine Registration Administration and Quality Safety Supervision was held in Guangzhou.

The meeting was guided by Comrade Xi JinPing’s Thought on Socialism with Chinese Characteristics for a New Era, fully implemented the guiding principles from the 20th National Congress of the Communist Party of China and all previous plenary sessions of the 20th Central Committee, and carried out the requirements set forth at the national work conference on drug regulation. It reviewed the work accomplished in 2025 and during the 14th Five-Year Plan period, analyzed the current situation and challenges, and studied and planned the key tasks for 2026. Yang Sheng, Member of the Party Leadership Group and Deputy Commissioner of the National Medical Products Administration, attended the meeting and delivered a speech.

Learn more

News Information